Past News
2009
Sirius Genomics Announces Change in Leadership
December 2009Sirius Genomics, announced today that Chris Wagner has been appointed President and Chief Executive Officer, replacing Dr. Brad Popovich. Dr. Popovich will continue as a member of Sirius Genomics Board and will continue to assist Mr. Wagner and the Company with the provision of strategic advice and support. Read the full press release here.
Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris
July 2009Sirius Genomics, a developer of pharmacogenomic diagnostics, announced that it has signed a collaborative agreement with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic correlations in severe sepsis patients. The agreement focuses on the continued development of Sirius' pharmacogenomic diagnostic intended to assess responsiveness to recombinant human activated Protein C (sold by Eli Lilly and Company under the trademark Xigris ®) in patients with severe sepsis at high risk of death.
New Collaboration with Vanderbilt University
May 2009Sirius Genomics announced that it has signed a collaborative agreement with Vanderbilt University to study patients enrolled in Vanderbilt's Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study. The agreement focuses on the continued development of Sirius' first pharmacogenomic diagnostic which is intended to assess responsiveness to recombinant human activated Protein C (sold by Eli Lilly and Company under the trademark Xigris ®).
Sirius highlighted in recent article on Xigris and personalized medicine
March 2009In the article, Sirius Genomics is mentioned as a company that could potentially help Eli Lilly resurrect its drug, recombinant activated Protein C also known as Xigris. Read the full article here.
Sirius selected as an Emerging Rocket Company for the second year
January 27, 2009The Emerging Rockets list profiles technology companies from multiple technology sectors with great potential for investment and market breakthroughs in the coming year.
New Collaboration with UK Critical Care Genomics Group
January 2009Sirius Genomics announced that it has signed a collaborative agreement with the United Kingdom Critical Care Genomics (UKCCG) Group. The agreement focuses on the continued development of Sirius' pharmacogenomic diagnostic for responsiveness to recombinant activated Protein C (sold by Eli Lilly and Company under the trademark Xigris ®).
2008
Appointment of new Director for the Company
October 2008Mr. Patrick Terry joins Sirius' Board of Directors. As one of the co-founders of Genomic Health, a leading molecular diagnostic company, Mr. Terry brings his expertise in the field of personalized medicine to Sirius.
Appointment of Senior Vice President, Clinical & Regulatory Affairs
October 2008Alexandra Mancini joins Sirius as the new Senior Vice President, Clinical and Regulatory Affairs. Ms. Mancini brings her 25 years of experience in clinical trial implementation and regulatory process management expertise to Sirius.
Appointment of new Director for the Company
January 2008Dr. H. Christian Fibiger joins Sirius' Board of Directors. Dr. Fibiger was previously the Vice President and Global Head of Neuroscience at Amgen. He brings his deep understanding of the drug development process to Sirius.
Sirius selected as an Emerging Rocket Company for 2008 by Rocket Builders
January 24, 2008The Emerging Rockets list profiles technology companies from multiple technology sectors with great potential for investment and market breakthroughs in the coming year.
Appointment of new Director for the Company
January 23, 2008Dr. Heiner Dreismann joins Sirius' Board of Directors. As past CEO of Roche Molecular Systems, Dr. Dreismann is a veteran of the molecular diagnostic industry and brings his 20 years of extensive management and business experience to Sirius.
2007
Appointment of Vice President, Business Development
September 10, 2007Chris Wagner joins Sirius Genomics as Vice President, Business Development. Mr. Wagner brings 15 years of collective experience in marketing, sales and business development to Sirius. Celia Courchene will now focus on internal development taking the role of Vice President, Corporate Affairs.
Appointment of Vice President, Intellectual Property
August 13, 2007Jennifer Kaufman-Shaw joins Sirius Genomics as the new Vice President, Intellectual Property. Dr. Kaufman-Shaw brings her expertise as scientific patent counsel with over 15 years of legal experience to Sirius.
New Website Launched
March 22, 2007Sirius Genomics launched new website and logo.
2006
Appointment of Vice President, Business Development
October 1, 2006Celia Courchene joined Sirius as the new Vice President, Business Development. Ms Courchene brings 20 years of experience and expertise in business development and business law to the Company.
Closing of Series A Financing
June 23, 2006Sirius Genomics closed it Series A Financing raising $6.3 million.
Signing of Sirius-Tm Bioscience Agreement
March 17, 2006Sirius Genomics and Tm Bioscience sign a development and license agreement to jointly collaborate on the development and commercialization of diagnostic kits to identify patients who will respond to current available treatments for sepsis.
Appointment of new CEO
February 1, 2006Sirius Genomics is pleased to announce the recent appointment of Dr. Brad Popovich as President and CEO. Dr. Popovich joined the company last year as Chief Operating Officer. Dr. James Russell, former President and CEO, has been appointed as Chief Medical Officer in order to refocus his scientific expertise to expand the research, discovery and development side of the company.